FDA warns Sunrise on misbranded OTCs
This article was originally published in The Tan Sheet
Executive SummarySunrise Pharmaceutical Inc. makes non-monograph label claims for its diphenhydramine OTC products, rendering them unapproved new drugs, according to an FDA warning letter. The generic drug manufacturer claims its generic version of Johnson & Johnson's Benadryl is for temporary relief of hay fever and upper respiratory allergies - indications not in compliance with the antihistamine final monograph, according to the agency. The Jan. 14 warning letter also cites Rahway, N.J.-based Sunrise for a noncompliant Reye's syndrome warning on aspirin product labeling. FDA found multiple other violations relating to OTC labels and prescription drug good manufacturing practices during its inspection of Sunrise in June and July 2009
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.